Literature DB >> 16355411

Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation.

Arno Wutzl1, Wolfgang Brozek, Isolde Lernbass, Martina Rauner, Guenter Hofbauer, Christian Schopper, Franz Watzinger, Meinrad Peterlik, Peter Pietschmann.   

Abstract

Bone regeneration is required for fracture-healing, and different procedures have been used to promote osteogenesis. Recently, BMP-2 has been shown to induce bone formation in vivo and has been tested in clinical trials. A recent in vitro study evaluated the osteogenic activity of 14 BMPs on osteoblastic progenitor cells with an osteogenic hierarchical model in which BMP-2 and BMP-6 may play an important role in inducing osteoblast differentiation. Although the relative osteoinductive activity of each BMP is important, bone regeneration is a process consisting of bone formation and bone resorption. Therefore, it remains unclear which effects BMP-5 and -6 have on the generation of osteoclasts and by which mechanism osteoclastogenesis is stimulated. To compare osteoclastic potency of each BMP, primary murine bone marrow cells were treated with human recombinant BMP-2, BMP-5, or BMP-6 and 1,25-(OH)2 vitamin D3 and stained for the TRAP enzyme. Osteogenic activity of BMP-5 was determined by measuring induction of ALP-activity and proliferation after incubation with primary murine osteoblasts. For elucidating the molecular mechanism, primary bone marrow cells with various concentrations of OPG were added to the TRAP assay and mRNA levels of RANKL and OPG were measured after stimulation with BMP-5. The presented data show that BMP-5 and BMP-6, unlike BMP-2, enhanced the formation of murine TRAP+/MNCs in a biphasic curve. BMP-5 and -6 were less potent in stimulating osteoclastogenesis compared to BMP-2. Concerning the effects of BMP-5 on osteoblasts, there was a dose-dependent increase of ALP activity and proliferation up to a maximum dose of 300 ng/mL. At the mRNA level, BMP-5 increased the RANKL/OPG ratio. In conclusion, this study demonstrates that in contrast to BMP-2, BMP-5 and -6 influences the generation of osteoclasts in a biphasic mode. Both proteins might be very important regulators of bone homeostasis, and therefore, potent candidates for future treatment strategies of bone regeneration. (c) 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16355411     DOI: 10.1002/jbm.a.30615

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  21 in total

Review 1.  Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence.

Authors:  P V Giannoudis; N K Kanakaris; T A Einhorn
Journal:  Osteoporos Int       Date:  2007-08-12       Impact factor: 4.507

2.  Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice.

Authors:  Daniel B Dean; John T Watson; Wu Jin; Charlie Peters; J T Enders; Andrew Chen; Berton R Moed; Zijun Zhang
Journal:  J Anat       Date:  2010-03-05       Impact factor: 2.610

3.  Bone morphogenetic protein 2 stimulates endochondral ossification by regulating periosteal cell fate during bone repair.

Authors:  Yan Yiu Yu; Shirley Lieu; Chuanyong Lu; Céline Colnot
Journal:  Bone       Date:  2010-03-27       Impact factor: 4.398

Review 4.  The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing.

Authors:  Slobodan Vukicevic; Hermann Oppermann; Donatella Verbanac; Morana Jankolija; Irena Popek; Jasna Curak; Jelena Brkljacic; Martina Pauk; Igor Erjavec; Igor Francetic; Ivo Dumic-Cule; Mislav Jelic; Dragan Durdevic; Tomislav Vlahovic; Ruder Novak; Vera Kufner; Tatjana Bordukalo Niksic; Marija Kozlovic; Zrinka Banic Tomisic; Jadranka Bubic-Spoljar; Ivancica Bastalic; Smiljka Vikic-Topic; Mihaela Peric; Marko Pecina; Lovorka Grgurevic
Journal:  Int Orthop       Date:  2013-12-19       Impact factor: 3.075

5.  Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.

Authors:  Lance W Middleton; Zhewei Shen; Sushama Varma; Anna S Pollack; Xue Gong; Shirley Zhu; Chunfang Zhu; Joseph W Foley; Sujay Vennam; Robert T Sweeney; Karen Tu; Jewison Biscocho; Okyaz Eminaga; Rosalie Nolley; Robert Tibshirani; James D Brooks; Robert B West; Jonathan R Pollack
Journal:  JCI Insight       Date:  2019-05-16

6.  Myosin X regulates sealing zone patterning in osteoclasts through linkage of podosomes and microtubules.

Authors:  Brooke K McMichael; Richard E Cheney; Beth S Lee
Journal:  J Biol Chem       Date:  2010-01-17       Impact factor: 5.157

7.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Authors:  A Seckinger; T Meissner; J Moreaux; H Goldschmidt; G M Fuhler; A Benner; M Hundemer; T Rème; J D Shaughnessy; B Barlogie; U Bertsch; J Hillengass; A D Ho; V Pantesco; A Jauch; J De Vos; J F Rossi; T Möhler; B Klein; D Hose
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

8.  Expression and synthesis of bone morphogenetic proteins by osteoclasts: a possible path to anabolic bone remodeling.

Authors:  Rama Garimella; Sarah E Tague; Jianghong Zhang; Frank Belibi; Niru Nahar; Ben Hua Sun; Karl Insogna; Jinxi Wang; H Clarke Anderson
Journal:  J Histochem Cytochem       Date:  2008-03-03       Impact factor: 2.479

9.  Comparative analysis of mouse-induced pluripotent stem cells and mesenchymal stem cells during osteogenic differentiation in vitro.

Authors:  Hiroshi Egusa; Hiroki Kayashima; Jiro Miura; Shinya Uraguchi; Fangfang Wang; Hiroko Okawa; Jun-Ichi Sasaki; Makio Saeki; Takuya Matsumoto; Hirofumi Yatani
Journal:  Stem Cells Dev       Date:  2014-05-27       Impact factor: 3.272

10.  Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease.

Authors:  Larry J Suva; Eric Hartman; Joshua D Dilley; Susan Russell; Nisreen S Akel; Robert A Skinner; William R Hogue; Ulrich Budde; Kottayil I Varughese; Taisuke Kanaji; Jerry Ware
Journal:  Am J Pathol       Date:  2008-01-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.